Indication
Atrophy of vulva
Atrophy of the vulva is a degenerative dermatologic and gynecologic condition characterized by progressive thinning, drying, and loss of elasticity of the external female genitalia. Read more about Atrophy of vulva
107 drugs 55 manufacturers
Drugs that treat it
Common Atrophy of vulva therapies.
ESTRADIOL (TWICE WEEKLY) (estradiol)
ESTRADIOL
ESTRADIOL (ONCE WEEKLY) (estradiol)
ESTRADIOL (TWICE WEEKLY) (estradiol)
ESTRADIOL-NORETHINDRONE ACETAT (estradiol/norethindrone acetate)
VIVELLE-DOT (estradiol)
ESTRADIOL
ABIGALE LO (estradiol/norethindrone acetate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAtrophy of the vulva is a degenerative dermatologic and gynecologic condition characterized by progressive thinning, drying, and loss of elasticity of the external female genitalia.
Most commonly affecting postmenopausal individuals or those in hypoestrogenic states, it frequently manifests as part of vulvovaginal atrophy and the genitourinary syndrome of menopause.
Pathophysiologically driven by reduced circulating estrogen, the condition results in collagen depletion, diminished vascular perfusion, and structural regression such as flattening of the labia, loss of subcutaneous fat, and tissue friability.
Clinically, affected patients present with localized dryness, pruritus, burning, introital stenosis, and dyspareunia.
- medlineplus.gov
Atrophy of the vulva is a degenerative dermatologic and gynecologic condition characterized by progressive thinning, drying, and loss of elasticity of the external female genitalia
- dermnetnz.org
Atrophy of the vulva is a degenerative dermatologic and gynecologic condition characterized by progressive thinning, drying, and loss of elasticity of the external female genitalia Pathophysiologically driven by reduced circulating estrogen, the condition results in collagen depletion, diminished vascular perfusion, and structural regression such as flattening of the labia, loss of subcutaneous fat, and tissue friability Clinically, affected patients present with localized dryness, pruritus, bur...
- nih.gov
Most commonly affecting postmenopausal individuals or those in hypoestrogenic states, it frequently manifests as part of vulvovaginal atrophy and the genitourinary syndrome of menopause
- nih.gov
Most commonly affecting postmenopausal individuals or those in hypoestrogenic states, it frequently manifests as part of vulvovaginal atrophy and the genitourinary syndrome of menopause
- nih.gov
Most commonly affecting postmenopausal individuals or those in hypoestrogenic states, it frequently manifests as part of vulvovaginal atrophy and the genitourinary syndrome of menopause Pathophysiologically driven by reduced circulating estrogen, the condition results in collagen depletion, diminished vascular perfusion, and structural regression such as flattening of the labia, loss of subcutaneous fat, and tissue friability
- uva.nl
Pathophysiologically driven by reduced circulating estrogen, the condition results in collagen depletion, diminished vascular perfusion, and structural regression such as flattening of the labia, loss of subcutaneous fat, and tissue friability Clinically, affected patients present with localized dryness, pruritus, burning, introital stenosis, and dyspareunia
- nih.gov
Clinically, affected patients present with localized dryness, pruritus, burning, introital stenosis, and dyspareunia
Personalize your experience
Follow Atrophy of vulva and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.